HK1173380A1 - Co-crystals of tramadol and coxibs - Google Patents

Co-crystals of tramadol and coxibs

Info

Publication number
HK1173380A1
HK1173380A1 HK13100720.2A HK13100720A HK1173380A1 HK 1173380 A1 HK1173380 A1 HK 1173380A1 HK 13100720 A HK13100720 A HK 13100720A HK 1173380 A1 HK1173380 A1 HK 1173380A1
Authority
HK
Hong Kong
Prior art keywords
tramadol
coxibs
crystals
crystal
celecoxib
Prior art date
Application number
HK13100720.2A
Other languages
English (en)
Inventor
Salaman Carlos Ramon Plata
Nicolas Tesson
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/007451 external-priority patent/WO2010043412A1/en
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of HK1173380A1 publication Critical patent/HK1173380A1/

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK13100720.2A 2009-10-16 2013-01-17 Co-crystals of tramadol and coxibs HK1173380A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2009/007451 WO2010043412A1 (en) 2008-10-17 2009-10-16 Co-crystals of tramadol and nsaids
PCT/EP2010/002385 WO2011044962A1 (en) 2009-10-16 2010-04-19 Co-crystals of tramadol and coxibs

Publications (1)

Publication Number Publication Date
HK1173380A1 true HK1173380A1 (en) 2013-05-16

Family

ID=42272447

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13100720.2A HK1173380A1 (en) 2009-10-16 2013-01-17 Co-crystals of tramadol and coxibs

Country Status (20)

Country Link
US (1) US20230057884A1 ( )
JP (1) JP5399564B2 ( )
KR (1) KR101471585B1 ( )
CN (3) CN104844513B ( )
AR (1) AR079008A1 ( )
AU (1) AU2010306168B2 ( )
BR (1) BR112012005011B8 ( )
CA (1) CA2771665C ( )
CO (1) CO6511248A2 ( )
HK (1) HK1173380A1 ( )
HR (1) HRP20130316T1 ( )
IL (1) IL218256A ( )
MA (1) MA33742B1 ( )
MX (1) MX2012003050A ( )
NZ (1) NZ598353A ( )
PT (1) PT2488169E ( )
SG (1) SG178835A1 ( )
TW (1) TWI441630B ( )
WO (1) WO2011044962A1 ( )
ZA (1) ZA201201892B ( )

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
MX2016006464A (es) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
CN107648228A (zh) * 2017-10-24 2018-02-02 珠海赛隆药业股份有限公司 一种帕瑞昔布钠与盐酸曲马多组成的复合物及其用途
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN113825501A (zh) 2019-05-14 2021-12-21 埃斯蒂文制药股份有限公司 曲马多和塞来昔布的共晶体用于治疗疼痛同时降低曲马多的滥用倾向的用途
CN112007024A (zh) * 2019-05-28 2020-12-01 江苏恒瑞医药股份有限公司 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
WO2008085674A1 (en) * 2007-01-04 2008-07-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising celecoxib co-crystals
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination

Also Published As

Publication number Publication date
MA33742B1 (fr) 2012-11-01
TWI441630B (zh) 2014-06-21
CO6511248A2 (es) 2012-08-31
CN104817501A (zh) 2015-08-05
AR079008A1 (es) 2011-12-21
TW201116273A (en) 2011-05-16
BR112012005011B8 (pt) 2021-05-25
CA2771665C (en) 2015-10-06
AU2010306168B2 (en) 2014-10-30
JP2013507402A (ja) 2013-03-04
SG178835A1 (en) 2012-05-30
CN104844513B (zh) 2018-08-07
CN102573825A (zh) 2012-07-11
US20230057884A1 (en) 2023-02-23
AU2010306168A1 (en) 2012-03-15
MX2012003050A (es) 2012-05-29
BR112012005011B1 (pt) 2021-01-19
KR101471585B1 (ko) 2014-12-10
CN102573825B (zh) 2015-04-22
NZ598353A (en) 2014-01-31
CA2771665A1 (en) 2011-04-21
KR20120099212A (ko) 2012-09-07
IL218256A0 (en) 2012-04-30
JP5399564B2 (ja) 2014-01-29
WO2011044962A1 (en) 2011-04-21
HRP20130316T1 (en) 2013-05-31
CN104844513A (zh) 2015-08-19
PT2488169E (pt) 2013-04-03
CN104817501B (zh) 2017-09-22
IL218256A (en) 2017-05-29
BR112012005011A2 (pt) 2016-05-03
ZA201201892B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
UA109534C2 (uk) Співкристали трамадолу і коксибів
TN2012000515A1 (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
HK1173380A1 (en) Co-crystals of tramadol and coxibs
GB0620385D0 (en) Novel compounds
IN2012DN02805A ( )
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
MX2013008478A (es) 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2).
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
ATE498396T1 (de) Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes
WO2008043788A3 (en) Novel compounds
TW200728281A (en) Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
TN2012000075A1 (en) Co-crystals of tramadol and coxibs
CL2008001690A1 (es) Compuestos derivados de oxazolidinonas; su procedimiento de preparacion; y sus usos para preparar un medicamento.
MX2012006217A (es) Derivados de peroxido nuevos, su proceso de preparacion y su uso en medicina humana y en cosmeticos para el tratamiento o prevencion de acne.
WO2010027189A3 (ko) 호모아이소플라베논 또는 이의 염의 신규한 용도
TN2010000431A1 (en) New formulations, tablets comprising such formulations, their use and process for their preparation
WO2011076420A3 (en) Co-crystals of venlafaxine and celecoxib
UA42862U (uk) ЗАСТОСУВАННЯ М'ЯКОЇ ЛІКАРСЬКОЇ ФОРМИ, ЯКА МІСТИТЬ АКТИВНУ РЕЧОВИНУ β-ФЕНІЛЕТИЛАМІД 2-ОКСИСУКЦИНАНІЛОВОЇ КИСЛОТИ, ДЛЯ ЛІКУВАННЯ ОПІКОВИХ УРАЖЕНЬ ШКІРИ